Ascentage Pharma (AAPG) said Monday it priced an offering of 22 million common shares at HK$68.60 ($8.74) per share.
The shares are being sold by a trust affiliated with Chief Executive Dajun Yang in an offshore placement outside the US, raising around HK$1.51 billion. The offering was oversubscribed by 8 times and is expected to close Thursday.
After the placement closes, the trust will reinvest by subscribing to 22 million new shares at the same price.
The proceeds will be used to support commercialization and patient access efforts, global clinical trials for key drug candidates, infrastructure improvements, and working capital, the company said.
Shares of Ascentage Pharma fell past 4% in recent trading activity.
Price: 36.64, Change: -1.60, Percent Change: -4.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.